Best Thing Since Statins?

A University College London team allocated over 17,500 adults to injections with semaglutide or placebo. Semaglutide (e.g. Ozempic), is an approved weight-loss medication. The subjects used were from 41 countries, with a body mass index over 27. All, had also experienced at least one cardiovascular event, such as a heart attack. The semaglutide injections appeared to reduce the risk of a subsequent heart attack, by 20%. This happened, whether or not the treatment reduced the subject's weight. It's suggested this drug has beneficial effects on the cardiovascular system, unrelated to its impact on obesity. The study's authors suggest that semaglutide is 'the best thing since statins' (https://www.theguardian.com/science/article/2024/may/14/weight-loss-drug-semaglutide-reduce-heart-attack-risk-study). One must be concerned about the apparent further medicalisation of what's generally a lifestyle choice. Even if it reduces the risk of a heart attack, is it really a good idea, to place substantial numbers of folk on extended semaglutide injections? This will be attractive to the manufacturers of the drug. It could encourage folk to live with an unhealthy and wasteful lifestyle. One becomes obese, when one consumes more calories one burns in exercise. This basic message is 'lost', if one can medicate the problem away. It also encourages overconsumption, in a world where food is unequally distributed.